Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study in patients with active mild-to-moderate ulcerative colitis; and SER-401, which is in Phase Ib study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. In addition, the company engages in the development of SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-109, a donor-derived purified bacterial spore-based microbiome therapeutic candidate that is in Phase III clinical trial to correct dysbiosis in the colonic microbiome in the setting of recurrent CDI. Further, it is developing SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study for CDI antibiotic treatment; and SER-155, a microbiome therapeutic candidate to correct dysbiosis in patients following allogeneic hematopoietic stem cell or solid organ transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-945-9626
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$28.27 million
Profitability
Miscellaneous
Employees145
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions
What is Seres Therapeutics' stock symbol?
Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."
How were Seres Therapeutics' earnings last quarter?
Seres Therapeutics Inc (NASDAQ:MCRB) released its quarterly earnings results on Wednesday, March, 6th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.67) by $0.15. The biotechnology company earned $10.63 million during the quarter, compared to the consensus estimate of $3.78 million. Seres Therapeutics had a negative net margin of 350.03% and a negative return on equity of 1,584.13%. View Seres Therapeutics' Earnings History.
When is Seres Therapeutics' next earnings date?
What price target have analysts set for MCRB?
6 analysts have issued 1-year price targets for Seres Therapeutics' shares. Their predictions range from $15.00 to $16.00. On average, they expect Seres Therapeutics' stock price to reach $15.3333 in the next twelve months. This suggests a possible upside of 122.2% from the stock's current price. View Analyst Price Targets for Seres Therapeutics.
What is the consensus analysts' recommendation for Seres Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seres Therapeutics.
Has Seres Therapeutics been receiving favorable news coverage?
Press coverage about MCRB stock has trended somewhat positive recently, according to InfoTrie. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Seres Therapeutics earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Seres Therapeutics' key competitors?
Some companies that are related to Seres Therapeutics include Clovis Oncology (CLVS), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Spectrum Pharmaceuticals (SPPI), TherapeuticsMD (TXMD), Clementia Pharmaceuticals (CMTA), Radius Health (RDUS), Amphastar Pharmaceuticals (AMPH), Dicerna Pharmaceuticals (DRNA), Omeros (OMER), Deciphera Pharmaceuticals (DCPH), Kiniksa Pharmaceuticals (KNSA), Y-mAbs Therapeutics (YMAB), Rhythm Pharmaceuticals (RYTM) and Vanda Pharmaceuticals (VNDA).
What other stocks do shareholders of Seres Therapeutics own?
Who are Seres Therapeutics' key executives?
Seres Therapeutics' management team includes the folowing people:
- Mr. Eric D. Shaff, Pres, CEO, Interim Principal Financial Officer & Director (Age 43)
- Dr. John G. Aunins, CTO and Exec. VP of Bioprocess & Manufacturing (Age 58)
- Dr. Matthew R. Henn, Exec. VP & Chief Scientific Officer (Age 44)
- Mr. Carlo Tanzi, VP of Investor Relations & Corp. Communications
- Mr. Thomas J. DesRosier, Chief Legal Officer, Exec. VP & Sec. (Age 64)
When did Seres Therapeutics IPO?
(MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.
How do I buy shares of Seres Therapeutics?
Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seres Therapeutics' stock price today?
One share of MCRB stock can currently be purchased for approximately $6.90.
How big of a company is Seres Therapeutics?
Seres Therapeutics has a market capitalization of $283.23 million and generates $28.27 million in revenue each year. The biotechnology company earns $-98,940,000.00 in net income (profit) each year or ($2.43) on an earnings per share basis. Seres Therapeutics employs 145 workers across the globe.
What is Seres Therapeutics' official website?
How can I contact Seres Therapeutics?
Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected]
MarketBeat Community Rating for Seres Therapeutics (NASDAQ MCRB)
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe MCRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
